Viewing nowBarretan Tablet 80mg (Valsartan)
Valsartan 80mg
Tablet · Prescription medication
CTC Bio Co., Ltd.

MFDS item code 201507763 · Approved 2015.11.19 · Insurance code 669501580
Treatment of essential hypertension; improvement of heart failure; reduction of the risk of death after myocardial infarction
This medication is used to control blood pressure in patients with essential hypertension. It is also effective for treating heart failure patients who are intolerant to ACE inhibitors (specifically those in NYHA class II to IV). After myocardial infarction, it helps to reduce the mortality risk in clinically stable patients with left ventricular dysfunction or systolic dysfunction. In summary, this drug is used for hypertension, heart failure, and reducing the mortality risk after myocardial infarction.
1. Essential hypertension Take with water during a meal or between meals. It is recommended that the medicine be taken at the same time each day, if possible (e.g., in the morning). 1) Adults: Regardless of sex or race, the recommended oral dose is 80 mg of valsartan once daily. The blood pressure-lowering effect appears gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg per day or a diuretic may be administered concomitantly. If additional blood pressure reduction is required, the dose may be increased to a maximum of 320 mg per day. 2) Elderly patients (75 years and older): Start treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg of this medicine once daily. (3) Creatinine clearance below 10 mL/min and patients receiving dialysis: Do not administer this medicine. 4) Patients with volume depletion: In patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), start treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, start treatment with 40 mg of this medicine once daily; the dose should not exceed 80 mg per day. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended initial dose is 40 mg of this medicine orally twice daily, and the dose may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, reduction of the diuretic dose should be considered. The maximum daily dose is 320 mg, given in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended initial dose is 20 mg of this medicine twice daily, followed over several weeks by dose increases, as tolerated by the patient, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary when creatinine clearance is 10 mL/min or greater. However, do not administer this medicine to patients with creatinine clearance below 10 mL/min or patients receiving dialysis because there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, it is preferable that the daily dose of this medicine not exceed 80 mg. If a dose of 80 mg or more per day is administered, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
Safety and efficacy have not been established in children and adolescents under 18 years of age. Safety and efficacy have not been established in children and adolescents under 18 years of age.
This medication can cause serious harm to the fetus if taken during pregnancy, especially in the second and third trimesters; therefore, it should be discontinued immediately if pregnancy is confirmed. It is safe to avoid this medication in patients with certain conditions, such as those with severe liver dysfunction, severe kidney impairment, pregnant women or women who may become pregnant, and individuals allergic to this drug or its components. Care should be taken when using this medication in elderly patients, patients with high potassium levels, patients with mild liver dysfunction, and those with heart disease, as side effects such as excessive lowering of blood pressure may occur; therefore, dosage adjustments and monitoring of the patient's condition should be done gradually. While taking this medicine, symptoms like headache, dizziness, cough, fatigue, and diarrhea may occur, and rarely serious allergic reactions, kidney function deterioration, or blood-related abnormalities may arise, so any unusual symptoms should be reported to healthcare professionals immediately. Particularly, this medication can cause a rapid drop in blood pressure; hence, caution should be observed for symptoms of hypotension when starting treatment or increasing the dose, and necessary measures should be taken as per the physician’s advice. Moreover, taking potassium-sparing diuretics or potassium supplements can lead to dangerously high potassium levels in the blood; thus, regular blood tests to check potassium levels are necessary when used together. This drug may interact with other antihypertensive agents or certain analgesics and anticoagulants, so if other medications are being taken, it is crucial to inform the doctor or pharmacist. Women who are pregnant or breastfeeding should avoid this medication; if it must be taken, breastfeeding should be discontinued. This drug is not recommended for use in children or adolescents under the age of 18 since its safety and efficacy have not been established. In cases of overdose, severe hypotension or loss of consciousness may occur, necessitating prompt medical treatment, and generally, dialysis is not effective. Finally, this medication should be kept out of reach of children, and transferring it to other containers is not advisable for maintaining quality.
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to air and moisture; therefore, it should be stored in a sealed container. Additionally, it should be kept in a cool place below 30 degrees Celsius to maintain efficacy.
Light pink, biconvex, round film-coated tablet
30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowValsartan 80mg
Tablet · Prescription medication
CTC Bio Co., Ltd.

Valsartan 80mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 160mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 40mg
Tablet · Prescription medication
Samsung Novartis Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan 320mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.